+
Site Tour
TRICLIP™
TRICUSPID
VALVE REPAIR
TRANSCATHETER
EDGE-TO-EDGE REPAIR (TEER)

 

TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive
treatment option for patients with symptomatic, severe tricuspid regurgitation (TR)
who are at high risk for surgery.1

A STATE-OF-THE-ART TREATMENT OPTION FOR PATIENTS AT HIGH RISK FOR SURGERY

TriClip TEER is a low-risk,11 non-surgical treatment option for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation, despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.2

TriClip™ Patient Story: Cruz

TriClip™ Patient Story: Narcisa

TriClip™ Patient Story: Javier

  • Transcatheter beating heart procedure - no cardiopulmonary bypass
  • Allows for real-time positioning and repositioning to optimize TR reduction
  • Femoral venous access
  • Can be used in a standard cath lab or hybrid room
  • No pre-procedural CT required
  • Fast recovery times; many patients go home the next day8
Reduced HFH & improved QoL12
  • Shortness of breath
  • Peripheral edema
  • Ascites
  • Fatigue
  • Declining exercise capacity
Current treatment options have limitations

For many patients with Functional Tricuspid Regurgitation (FTR), medical management is not enough.

MEDICAL THERAPY FOR TR HAS LITTLE IMPACT ON TR REDUCTION – 2 YEAR DATA6

66%

of patients with severe functional tricuspid regurgitation die within 5 years of medical management13


Most patients receive medical management until right heart failure or end-organ dysfunction appears.14

Surgery is high risk and often denied15,16

Surgery for TR is seldom performed. Factors prohibiting surgery include:

  • Limited clinical evidence15
  • Multiple comorbidities15
  • Advanced age15
  • High rate of adverse events17,18

LONG-TERM SURVIVAL ESTIMATES FOR ALL PATIENTS UNDERGOING SURGICAL TRICUSPID VALVE REPLACEMENT OR REPAIR11

    Connext
    Hub

    Learn emerging and established information on cardiovascular conditions and stroke prevention technologies.

    Find out more

     

    TV

    Discover MitraClip and TriClip G5 systems

    MitraClip & TriClip G5: Control meets Efficiency

    ESC Tutorial 2024 E.Donal | Hands-on

    ESC Tutorials 2024
    Procedural hands-on| All you need to know to treat Tricuspid Regurgitation with Transcatheter Edge-to-Edge Repair

    ESC Tutorial 2024 N.Brugger

    ESC Tutorials 2024
    Procedural hands-on| All you need to know to treat Mitral Regurgitation with Transcatheter Edge-to-Edge Repair

    ESC Tutorial 2024 E.Donal

    ESC Tutorials 2024
    Live echocardiography | Monitor and follow up your patients post Tricuspid Transcatheter Edge-to-Edge Repair procedure

    ESC Tutorial 2024 A.Coisne, M.Glaso

    ESC Tutorials 2024
    Live echocardiography | Diagnose, Screen and Refer your patients to Transcatheter Edge-to-Edge Repair

    ESC Tutorial 2024 R.S. von Bardeleben

    ESC Tutorials 2024
    Live echocardiography | Monitor and follow up your patients post Mitral Transcatheter Edge-to-Edge Repair procedure

    HFA Tutorial 2025 E. Donal | Case based

    HFA Tutorials 2025
    Case based | How to manage a Secondary AV valve disease, with a focus on Tricuspid

    HFA Tutorials 2025 E. Donal

    HFA Tutorials 2025
    Simulation & Hands-on | How to treat an HF patient with the TEER therapy

    HFA Tutorials 2025
    I. Stankovic

    HFA Tutorials 2025
    STRAIN and echo workshop | How to assess an HF patient

    T-TEER: Transcatheter Tricuspid Valve Repair - cases, tips, and tricks - 2025

    T-TEER: Transcatheter Tricuspid Valve Repair - cases, tips, and tricks

    References
    1. TriClip G5 System IFU
    2. Abbott. Data on file. PS2203200
    3. Abbott. Data on file. PS2203401
    4. Abbott. Data on file. PS2203500
    5. Abbott. Data on file. PS2203501
    6. Kar S, Makkar RR, Whisenant BK, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: The TRILUMINATE Pivotal Randomized Trial. Circulation. March 30, 2025. doi:10.1161/CIRCULATIONAHA.125.074536
    7. Estevez-Loureiro R. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 2-year Outcomes from the bRIGHT Trial. Presented at PCR London Valves on November 19-21, 2023; London, UK.
    8. Adams D, Sorajja P, et al. TRILUMINATE Pivotal: Outcomes of All Randomized and Single-arm Subjects with Transcatheter Tricuspid Valve Edge-to-Edge Repair for Tricuspid Regurgitation. Presented at TCT on October 24, 2023; San Francisco, CA; USA.
    9. Tang GHL, Hahn RT, Whisenant BK, et al. Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort. J Am Coll Cardiol. Published online 2025;85(3):235-246. doi:10.1016/j.jacc.2024.10.08
    10. Lurz P, Rommel KP, Schmitz T, et al. Real-world 1-year results of tricuspid edge-to-edge repair from the bRIGHT study. J Am Coll Cardiol. 2024;84(7):607-616. doi:10.1016/j.jacc.2024.05.006
    11. Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. NEJM. March 4, 2023. doi: 10.1056/NEJMoa2300525.
    12. www.mayoclinic.org. Accessed February 2024
    13. Benfari G, Antoine C, Mille WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation. 2019;140(3):196-206.
    14. Asmarats L, Puri R, Latib A, et al. Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. J Am Coll Cardiol. 2018;71(25):2935-2956.
    15. Enriquez-Sarano M, Messika-Zeitoun D, Topilsky Y, et al. Tricuspid regurgitation is a public health crisis [published online ahead of print November 9, 2019]. Prog Cardiovasc Dis. 2019;62(6):447-451. Doi:10.1016/j.pcad.2019.10.009.
    16. Wong WK, Chen SW, Chou AH, et al. Late outcomes of valve repair versus replacement in isolated and concomitant tricuspid valve surgery: a nationwide cohort study. J Am Heart Assoc. 2020;9(8):e015637. doi:10.1161/JAHA.119.015637.
    17. Zack CJ, Fender EA, Chandrashekar P, et al, National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol. 2017;70(24):2953–2960. doi:10.1016/j.jacc.2017.10.039.
    18. Chen Q, Bowdish ME, Malas J, et al. Isolated tricuspid operations: The Society of Thoracic Surgeons Adult cardiac surgery database analysis. Ann Thorac Surg. 2023;115(5):1162–1170. doi:10.1016/j.athoracsur.2022.12.041.Data on File at Abbott.
    19. Data on File at Abbott.
    20. Abbott. Data on file. RPT2139672
    21. Test(s) performed by and data on file at Abbott. (RPT2133700, RPT2122822-R, RPT2124838-R)
    22. Lurz P, et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 30-Day Results from the TriClip™ bRIGHT Study. Data presented at Euro PCR 2022.
    23. Tang, G, Hahn, R, Whisenant, B. et al. Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-Year Outcomes From the TRILUMINATE Randomized Cohort. JACC. 2025 Jan, 85 (3) 235-246. doi.org/10.1016/jjacc.2024.10.086

    © Abbott 2025. All rights reserved. 9-EH-5-14379-01 08-2025 REV F

    You are about to leave my-connext.com

    You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

    The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

    OK Decline